Investigation of Plasminogen Activator Inhibitor-1 4G/5G Gene Polymorphisim in Patients with Pre-Diagnosed Cerebrovascular Disease, Coagulation Disorder and Hypertension

Abstract

Plasminogen activator inhibitor-1 (PAI-1); gene polymorphism is the main inhibitor of fibrinolysis, and high levels may increase the risk of cardiovascular disease. The polymorphism of the 4G/5G gene is located in the PAI-1 gene promoter region. In this study, our objective is to investigate the genotype and allele distributions of PAI-1 gene polymorphisms in patients with cerebrovascular disease, coagulation disorder and those pre-diagnosed with hypertension. The results of the analysis PAI-1 gene polymorphism in 109 patients were evaluated retrospectively. These patients were divided into three groups as cerebrovascular disease, hypertension and coagulation disorder. In the analysis, CVD T (cardiovascular disease thrombosis) stripassay kit which is based on reverse hybridization technique was used. No statistically significant difference was found between three groups in terms of genotype and allele frequencies. PAI-1 4G/5G genotype in cerebrovascular disease and hypertension groups were found to be statistically significant compared with 4G/4G genotype, in terms of intra group comparison of genotype distrubutions of the group. In the group pre-diagnosed with coagulation disorder PAI-1 4G/5G genotype were found to be statistically significant compared with 4G/4G and 5G/5G. In conclusion; PAI-1 4G/5G genotype may be evaluated a risk factor in patients cerebrovascular disease, coagulation disorder and hypertension.